We enrolled 12 patients with severe sepsis or septic shock in the study (Supplement Fig. 1 ). Eight patients were randomized to receive pioglitazone and four patients received usual care (control). The demographic and clinical outcomes are demonstrated in Supplement Table 1 . Baseline characteristics were similar between groups.
The PK profiles for the eight subjects randomized to the pioglitazone group are illustrated in Fig. 1 . Because of the low concentration levels in some pioglitazone subjects we investigated whether the route of administration affected pioglitazone levels. The AUC estimates were higher for subjects who took pioglitazone by mouth (PO), and similar to those found in adolescents with type 2 diabetes [5] , compared to subjects who took pioglitazone by nasogastric (NG) tube [median 5162 ng h/ml (IQR 3114-8270) vs. 1579 (IQR 335-4020) respectively, p = 0.08] (Fig. 1c, d ). Concentration differences between PO and NG groups in our study are unknown and could be related to adherence to the tube, gastroparesis, and delayed gastric emptying or gastric pH.
During the study a total of 12 serious adverse events occurred but none were related to the study drug. The total number of non-serious adverse events was 76 but only three events were considered possibly related to the study medication. One subject developed a maculopapular rash and two subjects developed increased lipase.
Excluding the subject who required ECMO support, we examined the effect of pioglitazone AUC on inflammatory markers and found a high inverse correlation between inflammatory markers and pioglitazone AUC (p = 0.003). Individual inflammatory markers were plotted against study day. Age and gender effects were first tested for the selected biomarkers and found not significant. The resulting linear regression coefficients and their significance levels are summarized in Supplement Table 2 . We found that the AUC of pioglitazone was significantly associated with a reduction in IL-6, IL-8, resistin, and TNF-α. This is the first study, to our knowledge, to study pioglitazone as a potential sepsis therapy during critical illness. We demonstrate that pioglitazone is safe when administered to critically ill pediatric patients. Furthermore, pioglitazone exposure was associated with a reduction in inflammatory mediators.
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